Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy
Primary Purpose
Epilepsy
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)
Sponsored by
About this trial
This is an interventional treatment trial for Epilepsy focused on measuring seizure disorder,, seizures,, convulsions,, grand mal,, petit mal,, absence seizures,, repeated seizures,, children's seizures,, secondary epilepsy,, symptomatic epilepsy,, generalized seizures,, partial seizure,, focal seizure,, partial complex seizure,, anticonvulsant medication
Eligibility Criteria
Inclusion Criteria:
- Written Informed Consent
- Patients of both gender, aged from 18-75 years
- Diagnosis of epilepsy according to the diagnosis criteria of the DSM IV/ ICD 10 (especially G 40.1 /G 40.2/ G 40.3)
- Insufficient response to at least one attempt of treatment in medical history with anticonvulsive medication, dosed sufficiently long and high
- Antiepileptic Drugs (AED) therapy must be stable at a level that promises long-term continuity for at least 10 before study start and has to be continued for at least 3 months during treatment phase
Exclusion Criteria:
- Absence of Informed Consent
- Pregnancy
- Psychiatric diseases, especially post-traumatic stress disorder, obsessive-compulsive disorders, schizophrenia, Borderline personality disorders (BPD), character disorders as well as major depressive disorders, anxiety disorders and eating disorders as comorbidity.
- Abuse of drugs and alcohol until 12 weeks before study start
- Cerebrovascular diseases
- Dementia
- Severe traumatic brain injury in medical history including invasive and non-invasive methods of therapy (tumor surgery, "Gamma Knife Surgery")
- Indications of structural impairment of the basal ganglia or the brain stem
- active implants (e.g. cochlea implants, VNS, pacemaker)
- Severe neurological diseases (e.g. Morbus Parkinson, systemic neurologic diseases
- severe internistic diseases (e.g. arterial hypertension, respiratory failure)
- Bronchial asthma
- malignant diseases of any kind, within five years before study start
- Severe active infectious diseases (e.g. HIV, hepatitis)
- Bone diseases (e.g. Morbus Paget, recent fractures)
- Diseases of the ENT body system: Hearing loss of the left ear which is treated with a hearing instrument, all dermatologic and infectious diseases which affect the area around the pinna and the ear canal, severe malformation of the pinna
- Vagotomy
- Concurrent participation in other studies
- Other circumstances that in the opinion of the investigator might be an obstacle for enrolling the subject
Sites / Locations
- Epilepsiezentrum Erlangen
Outcomes
Primary Outcome Measures
Assessment of performance
rated by investigator
QOLIE-89 MADRS CCTE
Secondary Outcome Measures
Patient's subjective assessment of epileptic shocks
rated by patient. Subjective assessment of epileptic shocks and cognitive functions. Measured with "Erlanger Kognitionstest" (EKT)
Further assessment of performance
EEG long-term monitoring, MR spectroscopy
Assessment of Safety
Registration of (S)AEs and drop outs
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01178437
Brief Title
Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy
Official Title
Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy - a Prospective Pilot Study Regarding Safety, Effectiveness and Clinical Performance
Study Type
Interventional
2. Study Status
Record Verification Date
March 2011
Overall Recruitment Status
Completed
Study Start Date
August 2009 (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
January 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
cerbomed GmbH
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of the study is to prove the feasibility and safety of transcutaneous, electrical stimulation of the vagus nerve in patients with difficult-to-treat forms of epilepsy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy
Keywords
seizure disorder,, seizures,, convulsions,, grand mal,, petit mal,, absence seizures,, repeated seizures,, children's seizures,, secondary epilepsy,, symptomatic epilepsy,, generalized seizures,, partial seizure,, focal seizure,, partial complex seizure,, anticonvulsant medication
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
7 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)
Other Intervention Name(s)
T-VNS® Stimulator cM02
Intervention Description
daily, transcutaneous, electrical stimulation of the vagus nerve by the t-VNS device for a period of 9 months
Primary Outcome Measure Information:
Title
Assessment of performance
Description
rated by investigator
QOLIE-89 MADRS CCTE
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Patient's subjective assessment of epileptic shocks
Description
rated by patient. Subjective assessment of epileptic shocks and cognitive functions. Measured with "Erlanger Kognitionstest" (EKT)
Time Frame
9 months
Title
Further assessment of performance
Description
EEG long-term monitoring, MR spectroscopy
Time Frame
9 months
Title
Assessment of Safety
Description
Registration of (S)AEs and drop outs
Time Frame
9 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written Informed Consent
Patients of both gender, aged from 18-75 years
Diagnosis of epilepsy according to the diagnosis criteria of the DSM IV/ ICD 10 (especially G 40.1 /G 40.2/ G 40.3)
Insufficient response to at least one attempt of treatment in medical history with anticonvulsive medication, dosed sufficiently long and high
Antiepileptic Drugs (AED) therapy must be stable at a level that promises long-term continuity for at least 10 before study start and has to be continued for at least 3 months during treatment phase
Exclusion Criteria:
Absence of Informed Consent
Pregnancy
Psychiatric diseases, especially post-traumatic stress disorder, obsessive-compulsive disorders, schizophrenia, Borderline personality disorders (BPD), character disorders as well as major depressive disorders, anxiety disorders and eating disorders as comorbidity.
Abuse of drugs and alcohol until 12 weeks before study start
Cerebrovascular diseases
Dementia
Severe traumatic brain injury in medical history including invasive and non-invasive methods of therapy (tumor surgery, "Gamma Knife Surgery")
Indications of structural impairment of the basal ganglia or the brain stem
active implants (e.g. cochlea implants, VNS, pacemaker)
Severe neurological diseases (e.g. Morbus Parkinson, systemic neurologic diseases
severe internistic diseases (e.g. arterial hypertension, respiratory failure)
Bronchial asthma
malignant diseases of any kind, within five years before study start
Severe active infectious diseases (e.g. HIV, hepatitis)
Bone diseases (e.g. Morbus Paget, recent fractures)
Diseases of the ENT body system: Hearing loss of the left ear which is treated with a hearing instrument, all dermatologic and infectious diseases which affect the area around the pinna and the ear canal, severe malformation of the pinna
Vagotomy
Concurrent participation in other studies
Other circumstances that in the opinion of the investigator might be an obstacle for enrolling the subject
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefan Herrmann, MD
Organizational Affiliation
University of Erlangen-Nürnberg
Official's Role
Principal Investigator
Facility Information:
Facility Name
Epilepsiezentrum Erlangen
City
Erlangen
State/Province
Bavaria
ZIP/Postal Code
91054
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy
We'll reach out to this number within 24 hrs